A5068655451- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Botulinum Toxin and Related Neurological Disorders
- Genetic Neurodegenerative Diseases
- Obsessive-Compulsive Spectrum Disorders
- Glycogen Storage Diseases and Myoclonus
- Neurological and metabolic disorders
- Neurological diseases and metabolism
- Autism Spectrum Disorder Research
- Parkinson's Disease and Spinal Disorders
- Nuclear Receptors and Signaling
- Hereditary Neurological Disorders
- Genetics and Neurodevelopmental Disorders
- Psychosomatic Disorders and Their Treatments
- Autoimmune Neurological Disorders and Treatments
- Mitochondrial Function and Pathology
- Cancer Treatment and Pharmacology
- Restless Legs Syndrome Research
- Epilepsy research and treatment
- Transcranial Magnetic Stimulation Studies
- Cerebral Palsy and Movement Disorders
- Metabolism and Genetic Disorders
- RNA regulation and disease
- Attention Deficit Hyperactivity Disorder
- Trigeminal Neuralgia and Treatments
Baylor College of Medicine
2016-2025
St. Luke's Hospital
1999-2025
John Wiley & Sons (United States)
2019-2024
University of South Florida
2006-2024
Rush University Medical Center
2000-2024
Universidad de Guanajuato
2016-2024
Jagiellonian University
2024
Instituto Politécnico Nacional
2024
Neurological Research Institute
2021-2022
Texas Children's Hospital
2007-2022
We present a clinimetric assessment of the Movement Disorder Society (MDS)-sponsored revision Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UDPRS Task Force revised and expanded UPDRS using recommendations from published critique. MDS-UPDRS has four parts, namely, I: Non-motor Experiences Daily Living; II: Motor III: Examination; IV: Complications. Twenty questions are completed by patient/caregiver. Item-specific instructions an appendix complementary additional scales...
This article presents the revision process, major innovations, and clinimetric testing program for Movement Disorder Society (MDS)-sponsored of Unified Parkinson's Disease Rating Scale (UPDRS), known as MDS-UPDRS. The UPDRS is most widely used scale clinical study disease (PD). MDS previously organized a critique UPDRS, which cited many strengths, but recommended to accommodate new advances resolve problematic areas. An MDS-UPDRS committee prepared using recommendations published scale....
The DATATOP database, which includes clinical information on 800 patients with early untreated Parkinson9s disease (PD), is well suited to explore heterogeneity in PD. Patients early-onset PD (≤40 years, N = 33) reached the same level of disability as late-onset (≥70 85) group at a significantly slower rate (2.9 vs. 1.7 years). Early-onset functioned cognitively better than patients. Bradykinesia, and postural instability gait difficulty (PIGD), were more common onset rapid progression...
A therapy that slows disease progression is the major unmet need in Parkinson's disease.In this double-blind trial, we examined possibility rasagiline has disease-modifying effects disease. total of 1176 subjects with untreated were randomly assigned to receive (at a dose either 1 mg or 2 per day) for 72 weeks (the early-start group) placebo 36 followed by delayed-start group). To determine positive result dose, treatment group had meet each three hierarchical end points primary analysis...
To assess the safety, tolerability, and biological activity of glial cell line-derived neurotrophic factor (GDNF) administered by an implanted intracerebroventricular (ICV) catheter access port in advanced PD.GDNF is a peptide that promotes survival dopamine neurons. It improved 6-OHDA- or MPTP-induced behavioral deficits rodents monkeys.A multicenter, randomized, double-blind, placebo-controlled, sequential cohort study compared effects monthly ICV administration placebo 25, 75, 150, 300,...
Background Formulas were developed to define tremor dominant (TD) and postural instability/gait difficulty (PIGD) phenotypes of Parkinson's Disease (PD) using the Movement Disorder Society Unified Rating Scale (MDS‐UPDRS). TD PIGD designations, based on original (UPDRS), provided useful designations for classifying different PD. With advent MDS‐UPDRS, a valid set calculations these is needed. Methods UPDRS MDS‐UPDRS scores collected 877 PD patients. TD/PIGD calculated formula all Comparable...
It is not widely recognized that antipsychotic drugs can cause late-onset and persistent dystonia. This dystonia, which we call tardive to be distinguished from acute dystonic reactions, are transient, classic dyskinesia, a choreic disorder predominantly affects the oral region. We present 42 patients with The age of onset dystonia was 13 60 years. Symptoms began after 3 days 11 years therapy. Younger tended have more generalized In few patients, spontaneous remission occurred, but persisted...
Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson’s disease. Both DJ-1 α-synuclein, two proteins critically involved pathogenesis, have been tested as biomarkers several recent studies with inconsistent results. These largely due to variation protein species detected by different antibodies, limited numbers patients some studies, or inadequate control important variables. In this study, nature α-synuclein human cerebrospinal fluid was studied...
<h3>Background</h3> The best way to initiate dopaminergic therapy for early Parkinson disease remains unclear. <h3>Objective</h3> To compare initial treatment with pramipexole vs levodopa in disease, followed by supplementation, respect the development of motor complications, other adverse events, and functional quality-of-life outcomes. <h3>Design</h3> Multicenter, parallel-group, double-blind, randomized controlled trial. <h3>Setting</h3> Academic movement disorders clinics at 22 sites...
We studied the effects of botulinum A toxin in 12 patients with blepharospasm and 10 oromandibular-cervical dystonia received a double-blind manner. All improved, 71.6% on clinical rating score, 60.7% by self-assessment, 38.9% video-rating; there was no improvement placebo. The beneficial lasted mean 12.5 weeks (range, 5 to 28). Only 37.5% improved. Patients pharyngeal spasmodic dysphonia also
To study the development of freezing gait in PD.Freezing is a common, disabling, and poorly understood symptom PD.The authors analyzed data from 800 patients with early PD Deprenyl Tocopherol Antioxidative Therapy Parkinsonism (DATATOP) clinical trial who were assigned either placebo, deprenyl, tocopherol, or combination deprenyl tocopherol. The primary outcome measure was time randomization until score on Unified Parkinson's Disease Rating Scale (UPDRS) became positive.Fifty-seven (7.1%)...
<h3>Objective:</h3> To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity. <h3>Methods:</h3> We searched literature relevant articles classified them using 2004 AAN criteria. <h3>Results recommendations:</h3> Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) incobotulinumtoxinA (incoBoNT-A) are probably effective should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is...